Logo

American Heart Association

  30
  0


Final ID: Fri055

Machine Learning-Based Drug Screening Using Human iPS Cell-Derived Cardiac Tissues Identified A Novel Drug for Doxorubicin-Induced Cardiomyopathy

Abstract Body: Background: Cardiotoxicity is a life-threatening side effect of anti-cancer drugs like Doxorubicin (DOX). However, no effective treatments currently exist to mitigate drug-induced cardiac damage.
Research Questions: Can machine learning-based evaluation of sarcomere structures in human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes and contraction measurement in 3D functional cardiac tissues be applied for high-throughput screening for novel therapies?
Goals: To discover new therapeutics to prevent DOX-induced cardiac dysfunction.
Methods: We established a high-throughput screening assay integrating machine learning-based evaluation of cardiac damage in hiPSC-derived mature ventricular cardiomyocytes and functional evaluation of 3D mature cardiac tissues composed of hiPSC-ventricular cardiomyocytes and epicardial cells.
Results: DOX exposure caused sarcomere disorganization in 2D-cultured mature ventricular cardiomyocytes and contractile impairment in 3D cardiac tissues. We developed a supervised machine learning system to quantify sarcomere disorganization in 2D cardiomyocytes, enabling high-throughput screening and leading to the discovery of a novel drug that protects against DOX-induced sarcomere damage. The cardioprotective effect was validated in 3D mature cardiac tissues, where the drug improved contractile function under DOX exposure. Furthermore, in a DOX-induced cardiomyopathy mouse model, it also enhanced cardiac function and significantly increased survival.
Conclusion: This study highlights the potential of combining in vitro disease modeling with machine learning-based analysis for drug discovery. Our findings suggest that this novel drug could be an effective treatment for DOX-induced cardiomyopathy.
  • Funakoshi, Shunsuke  ( CiRA, Kyoto University , Kyoto , Japan )
  • Sasaki, Masako  ( CiRA, Kyoto University , Kyoto , Japan )
  • Kondo, Shigeru  ( Takeda Pharmaceutical Company Limit , Fujisawa , Japan )
  • Naka, Yuki  ( CiRA, Kyoto University , Kyoto , Japan )
  • Imahashi, Kenichi  ( Takeda Pharmaceutical Company Limit , Fujisawa , Japan )
  • Yoshida, Yoshinori  ( CiRA, Kyoto University , Kyoto , Japan )
  • Author Disclosures:
    Shunsuke Funakoshi: DO have relevant financial relationships ; Advisor:Orizuru Therapeutics:Active (exists now) | Masako Sasaki: No Answer | Shigeru Kondo: No Answer | Yuki Naka: No Answer | Kenichi Imahashi: No Answer | Yoshinori Yoshida: No Answer
Meeting Info:

Basic Cardiovascular Sciences 2025

2025

Baltimore, Maryland

Session Info:

Poster Session and Reception 3

Friday, 07/25/2025 , 04:30PM - 07:00PM

Poster Session and Reception

More abstracts on this topic:
Distinct Roles of Human Glycogenins in Glycogen Metabolism and Their Implications for Glycogen Storage Diseases

Weng Tzu Han, Pien Yu-chung, Chen Ching-jou, Chen Po-pang, Tseng Yu-ting, Chen Ying-chen, Lee Ying-ting, Hsia Kuo-chiang, Tsai Su-yi

A Curious Complete Heart Block with Carfilzomib

Shah Mohammed, Rahman Naveed, Al-mohamad Talal, Batra Sejal, Vyas Apurva

More abstracts from these authors:
Time-Course Single-Cell RNA Sequencing of Patient iPSC-Derived Heart Tissue Reveals Disease-Driving Pathways in Duchenne Muscular Dystrophy–Related Cardiomyopathy

Inazuka Fumika, Funakoshi Shunsuke, Hata Reo, Fujiwara Yuya, Ida Kazumi, Sakurai Hidetoshi, Yoshida Yoshinori

Generation of low-adsorption devise for engineered cardiac tissue

Fujiwara Yuya, Sasaki Masako, Funaoka Sohei, Yoshikuni Takuro, Ida Kazumi, Naka Yuki, Imahashi Kenichi, Yoshida Yoshinori

You have to be authorized to contact abstract author. Please, Login
Not Available